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Rapid Diagnosis of Azole-Resistant Aspergillosis by Direct PCR Using
Tissue Specimens
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We report the use of PCR techniques on a formalin-fixed and paraffin-embedded tissue specimen for direct
detection of one dominant azole resistance mechanism in a case of disseminated invasive aspergillosis. Rapid
detection of mutations associated with azole resistance directly in tissue significantly reduces diagnostic delay.
Invasive infections due to Aspergillus fumigatus are associ-
ated with significant morbidity and mortality, although the
prognosis of patients with invasive aspergillosis has improved
with the clinical use of mold-active antifungal azoles, most
notably voriconazole (9, 11). However, the survival of patients
may be threatened by the emergence of azole resistance of
aspergilli (1, 7, 13). Resistance is commonly due to point mu-
tations in the cyp51A gene, which is the target for antifungal
azoles (1, 4, 8, 13, 14). The isolates commonly exhibit a cross-
resistant phenotype (4), and patients with azole-resistant dis-
ease may fail azole therapy (1, 7, 10, 12). One problem in the
management of azole-resistant aspergillosis is the early detec-
tion of resistance as cultures are negative in up to 50% of
patients with focal pulmonary lesions (2), and in vitro suscep-
tibility testing takes at least 5 to 7 days to complete. In this
report, molecular tools were utilized to rapidly confirm the
diagnosis of disseminated azole-resistant aspergillosis.
Case report. A 60-year-old man was diagnosed with acute
myeloid leukemia and underwent an allogeneic hematopoietic
stem cell transplantation. Six months later, he developed grade
2 to 3 graft-versus-host disease (GvHD) of the gastrointestinal
tract and skin. He was treated with 1 mg prednisone/kg/day
plus 3 mg b.i.d. Entocort. His neutrophil count was 0.77 
109/liter. Diarrhea responded quickly. However, 10 days later,
he developed fever, and high-resolution computed tomography
(CT) of the thorax showed the presence of multiple nodular
pulmonary infiltrates. Aspergillus fumigatus was cultured from
the sputum, and circulating galactomannan was detected in
serum. Under the suspicion of invasive pulmonary aspergillo-
sis, treatment with voriconazole was started immediately, and
the prednisone dose was halved and, within a few weeks, fur-
ther reduced to a maintenance dose of 5 mg daily. The GvHD
did not relapse, but as the clinical condition of the patient did
not improve and sputum cultures remained positive with A.
fumigatus, caspofungin was added. One week after the start of
the antifungal therapy, paresis of the abducens nerve devel-
oped, and brain magnetic resonance imaging (MRI) showed
multiple lesions. A brain biopsy was performed, and histolog-
ical examination showed septate hyphae (Fig. 1); however,
cultures remained negative. The sputum isolate was resistant
to itraconazole and voriconazole and intermediate susceptible
to posaconazole (Table 1) (13). As the cerebral lesion might be
due to azole-resistant A. fumigatus, it was decided to replace
voriconazole by liposomal amphotericin B. The patient again
developed fever, and posaconazole was added to the treatment
regimen.
We utilized the sputum isolate and three formalin-fixed and
paraffin-embedded tissue sections from the brain biopsy for
identification of the resistance mechanism. Amplification of
the 28S ribosomal DNA confirmed the presence of Aspergillus
in the biopsy samples. Sequence-based analysis of the cyp51A
gene (using reference sequence of strain AF338659 from
GenBank) of the sputum isolate showed a substitution of
leucine for histidine at codon 98 and a 34-bp tandem repeat in
the gene promoter region (TRL98H). The morphological
species identification of A. fumigatus was confirmed by se-
quencing of the highly conserved -tubulin gene (7). Two PCR
assays (Table 2) targeted at the tandem repeat and the muta-
tion at codon 98 were performed directly on the brain biopsy
specimen and were both positive (Table 1). DNA was extracted
using proteinase K and the Qiagen EZ1 robot (Qiagen, The
Netherlands). For the real-time detection of L98H, a 122-bp
region was amplified, bridging codon 98 of the cyp51A gene by
using a forward primer and a reverse primer (Table 2). Using
hybridization probes, the wild-type L98 codon could be differ-
entiated from the mutated L98H codon. A sensor probe was
designed to span the mutation and to be separated from an
anchor probe by 1 nucleotide. The melting temperature (Tm)
of the sensor probe was approximately 6.6°C lower than that of
the anchor probe; a wild-type DNA template will result in a
mismatch giving a lower Tm than that observed for the mutated
DNA template. The LightCycler FastStart DNA Master Hyb-
Probe reaction mix was used.
To detect the 34-bp repetitive insertion, a TaqMan probe
(TR) (Table 2) was designed to bind to the last 13 bp and the
first 9 bp of the repetitive insertion, thereby binding specifically
to a mutated DNA template. To control for a successful am-
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plification of the 110-bp fragment of the promoter region by a
forward primer and a reverse primer of the cyp51A gene, an
additional TaqMan probe (wild-type sequence) (Table 2) was
designed to detect the gene in general, independent from the
presence of the repetition. Besides that, sequence analysis of a
160-bp fragment of the cyp51A gene from the biopsy sample
confirmed the presence of the TR in the A. fumigatus in the
tissue sample.
The clinical condition of the patient gradually improved, and
imaging showed regression of the pulmonary and brain lesions.
Liposomal amphotericin B and caspofungin therapy was dis-
continued after 12 weeks. Posaconazole was continued, and a
plasma level of 1.7 mg/liter was achieved. Repeat CT of the
brain showed further improvement of the lesions 6 months
after initiation of antifungal therapy.
Azole resistance has emerged in The Netherlands, and the
prevalence among clinical A. fumigatus isolates was 6% in 2007
(7). Resistance significantly complicates the treatment of inva-
FIG. 1. Histology of the brain biopsy specimen showing septate hyphae (PAS staining, 400 magnification).
TABLE 1. Results of the diagnostic assays for the clinical specimens obtained from the patient and for three controls
Date Sample Microscopy Culture Molecularidentificationa
Detected
cyp51A
substitutionb
MIC (mg/liter)c
AMB ITZ VCZ POS CAS
26 September
2008
Sputum Not done A. fumigatus A. fumigatus TRL98H 0.5 16 4 0.5 0.25
24 October Brain biopsy sample Septate hyphae Negative A. fumigatus TRL98H
2008 Lung biopsy sample
(control)
Septate hyphae A. fumigatus A. fumigatus TRL98H 0.25 16 4 0.5 0.5
Lung biopsy sample
(control)
Negative A. fumigatus A. fumigatus Negative 0.5 1 0.5 0.063 0.125
Brain biopsy sample
(control)
Negative Negative Negative Negative
a Molecular identification by sequencing the 28S ribosomal DNA directly on isolates if cultures were positive or directly on the tissue when cultures were negative.
b For the sputum isolate, the full sequence of the cyp51A gene was determined. For the biopsy specimens, two PCR assays were used to detect the tandem repeat
and L98H substitution directly on formalin-fixed, paraffin-embedded biopsy samples. TR, 34-bp tandem repeat; L98H, substitution of leucine for histidine at codon 98.
c MIC determined using the CLSI M38-A2 protocol. AMB, amphotericin B; ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; CAS, caspofungin. For
caspofungin, the minimum effective concentration was determined.
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sive aspergillosis, as alternative drugs with efficacy similar to
that of voriconazole in central nervous system aspergillosis are
not available (5, 6, 10). The TRL98H resistance mechanism
was found to be present in more than 90% of Dutch azole-
resistant A. fumigatus isolates and was always associated with a
multi-azole-resistant phenotype (7, 10, 12). In an experimental
model of disseminated aspergillosis, the efficacy of posacon-
azole against TRL98H isolates was reduced by 50% com-
pared to that of wild-type isolates (3). Furthermore, it remains
unclear if adequate posaconazole levels can be achieved at the
site of infection in the brain. Nevertheless, as there were no
oral alternatives, we used posaconazole for step-down therapy
in our patient and were able to obtain high plasma levels. The
lesions continued to improve during posaconazole mono-
therapy.
The detection of resistance in invasive aspergillosis may be
problematic, as positive cultures are required to test for a
resistant phenotype, while the infecting isolate is obtained in
only a minority of cases. However, even if Aspergillus is cul-
tured, adequate treatment may be delayed for 5 to 7 days due
to the time needed for MIC results to become available. Given
a median survival of central nervous system aspergillosis of
only 10 days (6), this is an unacceptable delay. Although in our
patient resistance was expected early due to MIC testing of the
sputum isolate, we were able to diagnose azole-resistant dis-
seminated aspergillosis directly in the brain biopsy by using
specifically designed real-time PCR assays. This appears to be
a feasible approach, as mutations in the cyp51A gene are the
primary mechanism of azole resistance in A. fumigatus, and the
TRL98H is the dominant change in Dutch azole-resistant A.
fumigatus isolates (7). Provided that the resistance mechanism
is known, molecular techniques are suitable to detect multiple
resistance mechanisms simultaneously.
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TABLE 2. PCR assays targeted at the tandem repeat and the mutation at codon 98
Targeta Primer Sequenceb Bindingpositions (bp)c
TR Forward primer 5-CAGCACCACTCCAGAGTTGTCT-3 8–29
Reverse primer 5-GTGTATGGTATGCTGGAACTACACCT-3 109–84
TaqMan probe (TR) 3-FAM-TGCTGAGCCGAATGAATCACGC-TMR-5 26–47
TaqMan probe (wild-type sequence) 3-FAM-ATTAGGCAACTTTCATTCGGCTCAGC-BBQ-5 78–53
L98H Forward primer 5-CAAAAAACCACAGTCTACCTG-3 658–678
Reverse primer 5-GAATTGGGACAATCATACACC-3 800–780
Sensor probe 5-ACGGCAAGCACAAGGATG-3, fluorescein-labeled 707–724
Anchor probe 5-CAATGCGGAAGAGGTCTATAGTCCATTGA-3-LC-red 640-labeled 723–754
a TR, 34-bp tandem repeat; L98H, substitution of leucine for histidine at codon 98.
b FAM, 6-carboxyfluorescein; TMR, 6-TAMRA (6-carboxytetramethylrhodamine); BBQ, 4.4-bis-(2-butyloctyloxy)-p-quaterphenyl; LC-red 640, LightCycler Red
640-aminohexyl-spacer-5-OH.
c Binding positions of oligonucleotides on the basis of reference strain AF 338659.
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